ceftazidime + ciprofloxacin

Ceftazidime + ciprofloxacin is a combination antibiotic therapy consisting of two active agents with complementary mechanisms of action used to treat bacterial infections, particularly those caused by resistant Gram-negative bacteria such as Pseudomonas aeruginosa. Ceftazidime is a third-generation cephalosporin beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell death. Ciprofloxacin is a second-generation fluoroquinolone that inhibits bacterial DNA replication by targeting DNA gyrase (topoisomerase II) and topoisomerase IV, preventing supercoiling and replication of bacterial DNA. The combination has been studied for synergy against multiresistant Pseudomonas aeruginosa isolates, showing enhanced antibacterial effects when used together without antagonism. This combination may be considered in clinical settings where resistance limits monotherapy options.

Other names

ceftazidime + ciprofloxacin